GSK plc - May 20, 2021 Form 4 Insider Report for Innoviva, Inc. (INVA)

Role
10%+ Owner
Signature
/s/ Victoria Whyte
Stock symbol
INVA
Transactions as of
May 20, 2021
Transactions value $
-$392,064,435
Form type
4
Date filed
5/24/2021, 05:04 PM
Next filing
Nov 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INVA Common Stock Sale -$392M -32M -100% $12.25 0 May 20, 2021 See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

GSK plc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Common stock sold pursuant to a share repurchase agreement by and between Glaxo Group Limited ("GGL"), an indirect wholly owned subsidiary of the Reporting Person, and Innoviva, Inc. (the "Issuer") dated as of May 20, 2021.
F2 Common Stock was held of record by GGL, an indirect wholly owned subsidiary of the Reporting Person.